<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mirtazapine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mirtazapine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mirtazapine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10872" href="/d/html/10872.html" rel="external">see "Mirtazapine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709090"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidality and antidepressant drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors. Mirtazapine is not approved for use in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F197109"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Remeron;</li>
<li>Remeron SolTab</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867580"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Mirtazapine;</li>
<li>Auro-Mirtazapine;</li>
<li>Auro-Mirtazapine OD;</li>
<li>MYLAN-Mirtazapine;</li>
<li>NRA-Mirtazapine;</li>
<li>PMS-Mirtazapine;</li>
<li>PRO-Mirtazapine;</li>
<li>Remeron;</li>
<li>Remeron RD;</li>
<li>SANDOZ Mirtazapine;</li>
<li>TEVA-Mirtazapine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F197140"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidepressant, Alpha-2 Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F197114"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe79a398-12af-4c27-ab60-10c69bc78bde">Headache, chronic tension-type, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Headache, chronic tension-type, prophylaxis (alternative agent) (off-label use):</b>
<b>Oral:</b> Initial: 15 mg once daily at bedtime; may increase after 1 week to 30 mg/day based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15159466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15159466'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b>
<b>Oral:</b> Initial: 15 mg once daily at bedtime; may increase dose in 15 mg increments at intervals of ≥1 week based on response and tolerability. Maximum dose: 45 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); however, doses up to 60 mg/day have been used in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VADoD.1','lexi-content-ref-22161405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VADoD.1','lexi-content-ref-22161405'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients nonresponsive to selective serotonin reuptake inhibitors (SSRIs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25081580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25081580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 15 mg once daily at bedtime; may increase in increments of 15 mg at intervals of no less than 1 week based on response and tolerability, up to a usual maximum of 45 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Average doses in clinical trials were ~30 mg/day; doses up to 60 mg/day have been evaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11712626','lexi-content-ref-24930788','lexi-content-ref-11593305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11712626','lexi-content-ref-24930788','lexi-content-ref-11593305'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy:</i></b> When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include prior history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Switching antidepressants: </i></b>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23879318','lexi-content-ref-Hirsch.1','lexi-content-ref-23459282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23879318','lexi-content-ref-Hirsch.1','lexi-content-ref-23459282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of mirtazapine.</p>
<p style="text-indent:0em;margin-left:4em;">Allow 14 days to elapse between discontinuing mirtazapine and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991400"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">There are no dosage adjustments provided in the manufacturer's labeling; however, clearance is decreased in kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Initial: 7.5 to 15 mg once daily; titrate slowly with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Unlikely to be significantly dialyzed due to high protein binding and large V<sub>d</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 7.5 to 15 mg once daily; titrate slowly with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32383050','lexi-content-ref-32547158','lexi-content-ref-22859791','lexi-content-ref-18649586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32383050','lexi-content-ref-32547158','lexi-content-ref-22859791','lexi-content-ref-18649586'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis</b>
<b>:</b> Unlikely to be significantly dialyzed due to high protein binding and large V<sub>d</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Initiate at 7.5 to 15 mg once daily and titrate slowly with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Initial: 7.5 to 15 mg once daily; titrate slowly with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Initial: 7.5 to 15 mg once daily; titrate slowly with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988614"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, dosage reductions may be necessary in patients with moderate to severe hepatic impairment (clearance may be decreased). Some experts recommend reducing initial dose by 50% and a maximum dose of 30 mg/day in patients with hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846','lexi-content-ref-25175904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846','lexi-content-ref-25175904'])">Ref</a></span>). Use with caution.</p></div>
<div class="block doe drugH1Div" id="F197115"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b>
<b>Oral:</b> Initial starting doses of 7.5 mg once daily at bedtime have been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VADoD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VADoD.1'])">Ref</a></span>). Use with caution; clearance may be reduced; refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy:</i></b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Switching antidepressants:</i></b> Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55154950"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used without a mood stabilizer) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent <b>mania</b> or <b>hypomania</b> in patients with unipolar major depressive disorder (MDD) treated with mirtazapine have been reported rarely. Although some of these cases occurred in patients receiving monotherapy at a therapeutic antidepressant dose, a number of the reports occurred in patients also receiving selective serotonin reuptake inhibitors (SSRIs) (or without a period of washout from a previous SSRI) or had potential risk factors for switching (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21692606','lexi-content-ref-26667012','lexi-content-ref-9671349','lexi-content-ref-25599460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21692606','lexi-content-ref-26667012','lexi-content-ref-9671349','lexi-content-ref-25599460'])">Ref</a></span>). It has also been suggested that mirtazapine-induced mania may present with atypical features, consisting of dysphoria, irritability, insomnia, psychomotor agitation, and abnormal gait (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12409687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12409687'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>). Mirtazapine induced-mania has been attributed to central norepinephrine hyperactivity through its unique mechanism of action of blocking central alpha-2 adrenergic autoreceptors and heteroreceptors, resulting in increased serotonin and norepinephrine neurotransmitter release while blocking postsynaptic 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12409687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12409687'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; among the limited case reports involving mirtazapine, the average time until onset of mania/hypomania following mirtazapine initiation or a dose increase was 15.7 days (median, 7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25599460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25599460'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12409687','lexi-content-ref-25599460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12409687','lexi-content-ref-25599460'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying brain dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12409687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12409687'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coadministration with certain SSRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12409687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12409687'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced movement disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine has been associated with several hyperkinetic movement disorders. Most case reports describe <b>akathisia, </b>acute <b>dystonia, </b>and<b> restless leg syndrome</b> (RLS). Mirtazapine-induced <b>dyskinesia</b> (including gradual onset, transient, and acute reversible) has also been reported rarely. Mirtazapine-induced akathisia is usually reported in the presence of higher mirtazapine doses (30 mg/day), whereas dystonia and dyskinesia are usually reported at lower doses (15 mg/day). Akathisia may also occur rarely at lower doses (15 mg/day) in select patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20739826','lexi-content-ref-11999246','lexi-content-ref-18626283','lexi-content-ref-30985094','lexi-content-ref-18756499','lexi-content-ref-28822709','lexi-content-ref-15732128','lexi-content-ref-20124786','lexi-content-ref-26702190','lexi-content-ref-32546134','lexi-content-ref-Yoon.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20739826','lexi-content-ref-11999246','lexi-content-ref-18626283','lexi-content-ref-30985094','lexi-content-ref-18756499','lexi-content-ref-28822709','lexi-content-ref-15732128','lexi-content-ref-20124786','lexi-content-ref-26702190','lexi-content-ref-32546134','lexi-content-ref-Yoon.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia: Dose-related (likely). Mechanism has not been clearly defined, although limited data attributes akathisia to blockade of alpha-2 adrenoreceptors from higher therapeutic dosages (ie, 30 mg/day) of mirtazapine, while lower dosage may be beneficial in the treatment of akathisia due to serotonin (5-HT<sub>2A</sub>) receptor blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16497273','lexi-content-ref-26557987','lexi-content-ref-26702190','lexi-content-ref-Yoon.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16497273','lexi-content-ref-26557987','lexi-content-ref-26702190','lexi-content-ref-Yoon.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dystonia: Unknown, but has been attributed to antidopaminergic action due to 5-HT<sub>2</sub> receptor inhibition associated with a central noradrenergic effect producing a noradrenergic-dopaminergic imbalance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Yoon.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Yoon.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">RLS: Unknown, but mirtazapine’s 5-HT<sub>1</sub> stimulating properties and 5-HT<sub>2</sub>/5-HT<sub>3</sub> receptor blocking properties have been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25716506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25716506'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dyskinesia: Unknown, but mediation by 5-HT<sub>2</sub> receptor antagonism has been suggested, which has been shown to have some activity promoting motor function in states of reduced dopamine release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20739826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20739826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; among the case reports of mirtazapine hyperkinetic movement disorders, symptom onset occurred within 9 days, with some cases following a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Yoon.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Yoon.2018'])">Ref</a></span>); however, there is also a case report of mirtazapine-induced akathisia following 20 years of continuous treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20124786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20124786'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Hyperkinetic movement disorders:</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced movement disorders/extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30985094','lexi-content-ref-20124786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30985094','lexi-content-ref-20124786'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine commonly causes <b>increased serum cholesterol </b>and, less commonly, <b>increased serum triglycerides</b>. Cases of severe <b>hypertriglyceridemia</b> and acute <b>pancreatitis</b> have also been reported rarely (some of the acute pancreatitis cases occurred in a setting of new-onset diabetes and/or diabetic ketoacidosis, making it difficult to determine whether hypertriglyceridemia was the cause) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29486665','lexi-content-ref-12885107','lexi-content-ref-26629801','lexi-content-ref-12927002','lexi-content-ref-23217660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29486665','lexi-content-ref-12885107','lexi-content-ref-26629801','lexi-content-ref-12927002','lexi-content-ref-23217660'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; in one study, increases in weight were linearly associated with changes in total cholesterol; however, the clinical significance is unclear, since increased cholesterol might be due to an improvement in depressive symptoms resulting in increased appetite, caloric intake, and weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12927002','lexi-content-ref-23217660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12927002','lexi-content-ref-23217660'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; increases in total cholesterol have been observed during the first 4 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12927002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12927002'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia</b>, <b>leukopenia,</b> and <b>agranulocytosis</b> have been reported rarely with mirtazapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12165012','lexi-content-ref-12680749','lexi-content-ref-19567774','lexi-content-ref-21057250','lexi-content-ref-11555082','lexi-content-ref-9352961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12165012','lexi-content-ref-12680749','lexi-content-ref-19567774','lexi-content-ref-21057250','lexi-content-ref-11555082','lexi-content-ref-9352961'])">Ref</a></span>). Mirtazapine is also associated with drug-induced <b>immune thrombocytopenia</b> (DITP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23121994','lexi-content-ref-12737939','lexi-content-ref-25118079','lexi-content-ref-32668640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23121994','lexi-content-ref-12737939','lexi-content-ref-25118079','lexi-content-ref-32668640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Leukopenia: Unclear and poorly understood; hypersensitivity/immune mediated mechanisms have been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21057250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21057250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">DITP: Non-dose-related; immunologic; mechanism is attributed to drug-dependent antibodies that react with the glycoprotein IIb/IIIa complex on the platelet surface resulting in accelerated platelet destruction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23121994','lexi-content-ref-23845922','lexi-content-ref-12737939','lexi-content-ref-32668640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23121994','lexi-content-ref-23845922','lexi-content-ref-12737939','lexi-content-ref-32668640'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21057250','lexi-content-ref-18098216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21057250','lexi-content-ref-18098216'])">Ref</a></span>). Drug-induced thrombocytopenia generally occurs 5 to 10 days after initial drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30504360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30504360'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine may cause <b>orthostatic hypotension</b> (eg, <b>dizziness</b>). The actual prevalence is unknown but is likely not common (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9352961','lexi-content-ref-12713682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9352961','lexi-content-ref-12713682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Orthostatic hypotension is likely caused by antagonism of alpha-1 adrenergic receptors; mirtazapine has weak peripheral alpha-1-blocking activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10446735','lexi-content-ref-9265949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10446735','lexi-content-ref-9265949'])">Ref</a></span>), although some authors have classified it as having moderate activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17785222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17785222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities) or cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Known predisposing conditions (hypovolemia/dehydration)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications predisposing patient to orthostatic hypotension (eg, antihypertensives)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (≥65 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sedation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sedation (<b>drowsiness</b>) is very common with initial use and may cause nonadherence, <b>dizziness, </b>and <b>confusion</b>, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11607047','lexi-content-ref-12680749','lexi-content-ref-9265949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11607047','lexi-content-ref-12680749','lexi-content-ref-9265949'])">Ref</a></span>). However, the dose relationship with mirtazapine is unique, in that lower doses (≤15 mg) are associated with significant sedation compared to less sedation with higher doses (&gt;15 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23813948','lexi-content-ref-28093029','lexi-content-ref-9352961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23813948','lexi-content-ref-28093029','lexi-content-ref-9352961'])">Ref</a></span>). Tolerance appears to develop to the sedative effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9265949','lexi-content-ref-12404669','lexi-content-ref-29626184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9265949','lexi-content-ref-12404669','lexi-content-ref-29626184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related (inverse relationship). Somnolence is primarily attributed to potent histamine H<sub>1</sub> antagonism at lower doses; higher doses are less sedating due to increased noradrenergic transmission which partially offsets the antihistamine activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23813948','lexi-content-ref-28093029','lexi-content-ref-9352961','lexi-content-ref-11001237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23813948','lexi-content-ref-28093029','lexi-content-ref-9352961','lexi-content-ref-11001237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; however, tolerance appears to develop quickly (within a few days) to the sedative effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9265949','lexi-content-ref-29626184','lexi-content-ref-11001237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9265949','lexi-content-ref-29626184','lexi-content-ref-11001237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of benzodiazepines or alcohol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported rarely with mirtazapine and typically occurs with coadministration of multiple serotonergic drugs, but can occur following a single serotonergic agent at high therapeutic doses or supratherapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24977717','lexi-content-ref-9695042','lexi-content-ref-22752315','lexi-content-ref-16005413','lexi-content-ref-14970364','lexi-content-ref-11351116','lexi-content-ref-27333965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24977717','lexi-content-ref-9695042','lexi-content-ref-22752315','lexi-content-ref-16005413','lexi-content-ref-14970364','lexi-content-ref-11351116','lexi-content-ref-27333965'])">Ref</a></span>). Only a few cases of serotonin syndrome have been reported with mirtazapine monotherapy at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11918514','lexi-content-ref-12671522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11918514','lexi-content-ref-12671522'])">Ref</a></span>). Of note, some clinicians have questioned whether serotonin syndrome attributed to mirtazapine is an accurate characterization or if symptoms described are due to other causes, such as extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24228948','lexi-content-ref-14646604','lexi-content-ref-16342227','lexi-content-ref-14646603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24228948','lexi-content-ref-14646604','lexi-content-ref-16342227','lexi-content-ref-14646603'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; mirtazapine, which does not inhibit the reuptake of serotonin, is sometimes classified as a noradrenergic and specific serotonergic antidepressant (NaSSA), and acts as an antagonist of presynaptic alpha-2 adrenergic receptors and postsynaptic 5-HT<sub>2</sub> and 5-HT<sub>3</sub> serotonin receptors, therefore leading to an increase in norepinephrine and 5-HT<sub>1A</sub>-mediated serotonin activity. Serotonin syndrome has been attributed to the serotonergic activity from stimulation of 5-HT<sub>1A</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24977717','lexi-content-ref-11607047','lexi-content-ref-22752315','lexi-content-ref-12671522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24977717','lexi-content-ref-11607047','lexi-content-ref-22752315','lexi-content-ref-12671522'])">Ref</a></span>); however, some clinicians have argued that the receptor pharmacology of mirtazapine is not consistent with it being able to cause serotonin toxicity, as it does not cause serotonin (5-HT) excess in the brain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14646604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14646604'])">Ref</a></span>)<i>.</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in most serotonin-syndrome cases (74%) (predominantly involving selective serotonin reuptake inhibitors, tricyclic antidepressants, and/or monoamine oxidase inhibitors [MAOIs]), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>). In the few cases involving mirtazapine, most occurred within 24 hours or several days following initiation or a dose increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24977717','lexi-content-ref-11918514','lexi-content-ref-12671522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24977717','lexi-content-ref-11918514','lexi-content-ref-12671522'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism (eg, MAOIs). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants, primarily the selective serotonin reuptake inhibitors, are commonly associated with <b>sexual disorders</b> in patients of any sex. Mirtazapine, however, is generally associated with having less risk for sexual adverse reactions and may also have some beneficial effects on sexual functioning in depressed patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21519537','lexi-content-ref-10431683','lexi-content-ref-19364298','lexi-content-ref-29955469','lexi-content-ref-20396434','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21519537','lexi-content-ref-10431683','lexi-content-ref-19364298','lexi-content-ref-29955469','lexi-content-ref-20396434','lexi-content-ref-26003261'])">Ref</a></span>). One meta-analysis also found no significant difference in treatment-emergent sexual dysfunction with mirtazapine compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19440080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19440080'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism attributed to mirtazapine’s role (if any) in sexual dysfunction is unknown, and because a large portion of sexual dysfunction is thought to be mediated via stimulation of the postsynaptic 5-HT<sub>2A</sub> receptor, the blockade of this receptor by mirtazapine should lead to a reduced incidence of these side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20396434','lexi-content-ref-12404669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20396434','lexi-content-ref-12404669'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (sexual dysfunction is commonly associated with depression; antidepressant-induced sexual dysfunction may be difficult to differentiate in treated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12243609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12243609'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of suicidal ideation and suicidal tendencies in pediatric and young adult patients (18 to 24 years of age) in short-term studies. In adults &gt;24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior and in older adults ≥65 years of age, a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21894129','lexi-content-ref-25693810','lexi-content-ref-17485726','lexi-content-ref-29734995','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-20146649','lexi-content-ref-12668373','lexi-content-ref-18056231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21894129','lexi-content-ref-25693810','lexi-content-ref-17485726','lexi-content-ref-29734995','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-20146649','lexi-content-ref-12668373','lexi-content-ref-18056231'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to long-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide is associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine commonly causes significant <b>weight gain </b>(increase of ≥7% of body weight) following short and long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12680749','lexi-content-ref-33022115','lexi-content-ref-16373922','lexi-content-ref-16649829','lexi-content-ref-12927002','lexi-content-ref-27593622','lexi-content-ref-21062615','lexi-content-ref-25467076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12680749','lexi-content-ref-33022115','lexi-content-ref-16373922','lexi-content-ref-16649829','lexi-content-ref-12927002','lexi-content-ref-27593622','lexi-content-ref-21062615','lexi-content-ref-25467076'])">Ref</a></span>). Mirtazapine also commonly causes <b>increased </b>
<b>appetite</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26629801','lexi-content-ref-30626746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26629801','lexi-content-ref-30626746'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Antidepressants may induce weight gain by interacting with central mechanisms regulating food intake and appetite, with differences in weight gain between agents attributed to actions on serotonergic, dopaminergic, noradrenergic, histaminergic, and cholinergic systems. Mirtazapine's weight gain has been attributed to its alpha-2 adrenoreceptor antagonism, its high affinity for antagonizing histamine (H<sub>1</sub>) receptors, and its effects on 5-HT<sub>2c</sub> receptors, as well as its low affinity for dopaminergic D<sub>1 </sub>and D<sub>2</sub> receptors<i>. </i>In addition, some of the weight gain may also reflect improvement in mood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21304130','lexi-content-ref-33022115','lexi-content-ref-30626746','lexi-content-ref-12404669','lexi-content-ref-21062615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21304130','lexi-content-ref-33022115','lexi-content-ref-30626746','lexi-content-ref-12404669','lexi-content-ref-21062615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; significant increases in weight have been observed after the first week of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21304130','lexi-content-ref-12518269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21304130','lexi-content-ref-12518269'])">Ref</a></span>). In one meta-analysis, mirtazapine was associated with significant weight gain during acute treatment (4 to 12 weeks), and maintained significant associations with weight gain over longer periods of use (≥8 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21062615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21062615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Psychiatric disorders (regardless of medication) are associated with a higher risk for obesity compared to the general population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21062615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21062615'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome </b>following mirtazapine discontinuation has been reported, primarily following abrupt discontinuation, although it has also occurred following gradual tapering. Reported symptoms include dizziness, nausea, vomiting, paresthesia, hypotension, insomnia, reduced need of sleep, anxiety, panic attacks, restlessness, irritability, elated mood, pressure of speech, increased energy, and nightmares (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9653542','lexi-content-ref-15014614','lexi-content-ref-Cosci.2017','lexi-content-ref-24926846','lexi-content-ref-23055861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9653542','lexi-content-ref-15014614','lexi-content-ref-Cosci.2017','lexi-content-ref-24926846','lexi-content-ref-23055861'])">Ref</a></span>). There is also a single case report of mirtazapine-withdrawal associated<b> pruritus</b> following abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31824812']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31824812'])">Ref</a></span>). In addition, there are several case reports describing withdrawal-induced<b> mania </b>or <b>hypomania </b>following both abrupt and gradual mirtazapine discontinuation. Some of the reports occurred in patients with bipolar disorder and some reports did not mention a preexisting diagnosis of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29694944','lexi-content-ref-12776393','lexi-content-ref-10789310','lexi-content-ref-29472753','lexi-content-ref-26816474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29694944','lexi-content-ref-12776393','lexi-content-ref-10789310','lexi-content-ref-29472753','lexi-content-ref-26816474'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; mechanism of withdrawal symptoms is unknown, but has been attributed, in part, to the sudden removal of the blockade of 5-HT receptors, as stimulation of 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors has been associated with nausea, anxiety, and insomnia. In addition, the sudden removal of histamine (H<sub>1</sub>) blockade may contribute to dizziness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9653542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9653542'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; case reports describe an onset of withdrawal symptoms between 1 to 7 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cosci.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cosci.2017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019','lexi-content-ref-15906018','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019','lexi-content-ref-15906018','lexi-content-ref-25677972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F197077"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum cholesterol (15%<span class="lexi-table-link-container"> (<a aria-label="Mirtazapine: Adverse Reaction: Increased Serum Cholesterol table link" class="lexi-table-link" data-table-id="lexi-content-mirtazapine-adverse-reaction-increased-serum-cholesterol" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mirtazapine-adverse-reaction-increased-serum-cholesterol')">table 1</a>)</span><span class="table-link" style="display:none;">Mirtazapine: Adverse Reaction: Increased Serum Cholesterol</span>), weight gain (12%; ≥7% of body weight: 8%; literature suggests that incidence of significant weight gain may be as high as 77% after 13.5 months of use)<span class="lexi-table-link-container"> (<a aria-label="Mirtazapine: Adverse Reaction: Weight Gain table link" class="lexi-table-link" data-table-id="lexi-content-mirtazapine-adverse-reaction-weight-gain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mirtazapine-adverse-reaction-weight-gain')">table 2</a>)</span><span class="table-link" style="display:none;">Mirtazapine: Adverse Reaction: Weight Gain</span> (Uguz 2015)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mirtazapine: Adverse Reaction: Increased Serum Cholesterol" frame="border" id="lexi-content-mirtazapine-adverse-reaction-increased-serum-cholesterol" rules="all">
<caption style="text-align:center;">
<b>Mirtazapine: Adverse Reaction: Increased Serum Cholesterol</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Nonfasting cholesterol increases to ≥20% above the upper limits</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mirtazapine: Adverse Reaction: Weight Gain" frame="border" id="lexi-content-mirtazapine-adverse-reaction-weight-gain" rules="all">
<caption style="text-align:center;">
<b>Mirtazapine: Adverse Reaction: Weight Gain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">361</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of body weight: 8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center"></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (13%), increased appetite (17%)<span class="lexi-table-link-container"> (<a aria-label="Mirtazapine: Adverse Reaction: Increased Appetite table link" class="lexi-table-link" data-table-id="lexi-content-mirtazapine-adverse-reaction-increased-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mirtazapine-adverse-reaction-increased-appetite')">table 3</a>)</span><span class="table-link" style="display:none;">Mirtazapine: Adverse Reaction: Increased Appetite</span>, xerostomia (25%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mirtazapine: Adverse Reaction: Increased Appetite" frame="border" id="lexi-content-mirtazapine-adverse-reaction-increased-appetite" rules="all">
<caption style="text-align:center;">
<b>Mirtazapine: Adverse Reaction: Increased Appetite</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">361</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (54%)<span class="lexi-table-link-container"> (<a aria-label="Mirtazapine: Adverse Reaction: Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-mirtazapine-adverse-reaction-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mirtazapine-adverse-reaction-drowsiness')">table 4</a>)</span><span class="table-link" style="display:none;">Mirtazapine: Adverse Reaction: Drowsiness</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mirtazapine: Adverse Reaction: Drowsiness" frame="border" id="lexi-content-mirtazapine-adverse-reaction-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Mirtazapine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">54%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">361</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (1%), hypertension, peripheral edema (2%), vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum triglycerides (6%)<span class="lexi-table-link-container"> (<a aria-label="Mirtazapine: Adverse Reaction: Increased Serum Triglycerides table link" class="lexi-table-link" data-table-id="lexi-content-mirtazapine-adverse-reaction-increased-serum-triglycerides" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mirtazapine-adverse-reaction-increased-serum-triglycerides')">table 5</a>)</span><span class="table-link" style="display:none;">Mirtazapine: Adverse Reaction: Increased Serum Triglycerides</span>, increased thirst</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mirtazapine: Adverse Reaction: Increased Serum Triglycerides" frame="border" id="lexi-content-mirtazapine-adverse-reaction-increased-serum-triglycerides" rules="all">
<caption style="text-align:center;">
<b>Mirtazapine: Adverse Reaction: Increased Serum Triglycerides</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Nonfasting triglyceride increases to ≥500 mg/dL</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (2%), urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≥3 times ULN: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (4%), abnormality in thinking (3%), amnesia, anxiety, apathy, asthenia (8%), confusion (2%)<span class="lexi-table-link-container"> (<a aria-label="Mirtazapine: Adverse Reaction: Confusion table link" class="lexi-table-link" data-table-id="lexi-content-mirtazapine-adverse-reaction-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mirtazapine-adverse-reaction-confusion')">table 6</a>)</span><span class="table-link" style="display:none;">Mirtazapine: Adverse Reaction: Confusion</span>, dizziness (7%)<span class="lexi-table-link-container"> (<a aria-label="Mirtazapine: Adverse Reaction: Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-mirtazapine-adverse-reaction-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mirtazapine-adverse-reaction-dizziness')">table 7</a>)</span><span class="table-link" style="display:none;">Mirtazapine: Adverse Reaction: Dizziness</span>, hypoesthesia, malaise, myasthenia, paresthesia, psychomotor agitation, tremor (2%), twitching, vertigo</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mirtazapine: Adverse Reaction: Confusion" frame="border" id="lexi-content-mirtazapine-adverse-reaction-confusion" rules="all">
<caption style="text-align:center;">
<b>Mirtazapine: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">361</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mirtazapine: Adverse Reaction: Dizziness" frame="border" id="lexi-content-mirtazapine-adverse-reaction-dizziness" rules="all">
<caption style="text-align:center;">
<b>Mirtazapine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirtazapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">453</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">361</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain (2%), hyperkinetic muscle activity, hypokinesia, myalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%), flu-like symptoms (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, atrial arrhythmia, bigeminy, bradycardia, cardiomegaly, chest pain, hypotension, left ventricular failure, phlebitis, pulmonary embolism, syncope, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cellulitis, exfoliative dermatitis, skin photosensitivity, Stevens-Johnson syndrome, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, dehydration, diabetes mellitus, goiter, heavy menstrual bleeding, hyponatremia, hypothyroidism, increased acid phosphatase, increased libido, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, cholecystitis, colitis, enlargement of abdomen, enlargement of salivary glands, eructation, gastritis, gastroenteritis, gingival hemorrhage, glossitis, intestinal obstruction, nausea, oral candidiasis, pancreatitis, sialorrhea, stomatitis, tongue discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast engorgement, breast hypertrophy, cystitis, dysmenorrhea, dysuria, ejaculatory disorder, hematuria, impotence, leukorrhea, mastalgia, urethritis, urinary incontinence, urinary retention, urinary urgency, uterine hemorrhage, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, leukopenia, pancytopenia, petechia, severe neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic cirrhosis, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia, altered sense of smell, aphasia, ataxia, cerebral ischemia, chills, delirium, delusion, dementia, depersonalization, drug dependence, dysarthria, emotional lability, euphoria, extrapyramidal reaction, hallucination, hostility, hyperacusis, hyperreflexia, hypomania, hypotonia, mania, migraine, myoclonus, neurosis, paranoid ideation, seizure, serotonin syndrome, stupor, tonic-clonic seizure, vascular headache, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, bone fracture (osteoporotic), dyskinesia, dystonia (including Pisa syndrome) (Yamada 2018), gout, myositis, neck pain, neck stiffness, ostealgia, rupture of tendon, tenosynovitis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation, accommodation disturbance, angle-closure glaucoma, blepharitis, conjunctivitis, diplopia, eye pain, nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, otalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis, polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Abnormal healing, fever, ulcer</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Orthostatic hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased serum creatine kinase, prolonged QT interval on ECG (Matsuda 2020), torsades de pointes, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous dermatitis, erythema multiforme, excoriation of skin (Keshtkarjahromi 2021), hyperpigmentation (Sukhdeo 2018), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (Duncan 2015), hyperprolactinemia, hypertriglyceridemia (Chen 2003, Duncan 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism, sexual disorder (Lee 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia (Stuhec 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Hui 2002), liver steatosis (Thomas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Neutropenic sepsis (Maidwell-Smith 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Complex sleep-related disorder (Shinith 2018), nightmares (Menon 2017), restless leg syndrome (precipitation or exacerbation) (Kolla 2018, Kim 2008), somnambulism (Yeh 2009), suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Khandat 2004)</p></div>
<div class="block coi drugH1Div" id="F197092"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, severe skin reactions, including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme, and toxic epidermal necrolysis) to mirtazapine or any component of the formulation; use of monoamine oxidase inhibitors (MAOIs), including linezolid or methylene blue IV (concurrently or within 14 days of stopping an MAOI).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F197074"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is low relative to other antidepressants.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Leach 2017; Rabenda 2013; Rizzoli 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May cause mild pupillary dilation which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and half-life and plasma concentrations are increased in mild to moderate impairment. Clinically significant transaminase elevations have been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; clearance is decreased with moderate and severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcohol use disorder, or concurrent therapy with medications that may lower seizure threshold.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Tablets may contain lactose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: SolTab formulation may contain phenylalanine.</p></div>
<div class="block foc drugH1Div" id="F197086"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remeron: 15 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remeron: 15 mg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remeron: 30 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remeron: 30 mg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.5 mg, 15 mg, 30 mg, 45 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remeron SolTab: 15 mg, 30 mg, 45 mg [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 45 mg</p></div>
<div class="block geq drugH1Div" id="F197070"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F197095"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Mirtazapine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $2.35 - $2.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $2.42 - $2.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $2.58 - $2.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Remeron SolTab Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $5.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $6.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $6.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mirtazapine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $2.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $2.70 - $2.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $2.77 - $2.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $2.83 - $2.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Remeron Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $7.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $7.59</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867581"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remeron: 30 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 45 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remeron RD: 15 mg, 30 mg, 45 mg [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 45 mg</p></div>
<div class="block adm drugH1Div" id="F197089"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablet: Do not remove tablet from blister pack until ready to administer; peel back foil to expose tablet; use dry hands to remove tablet and place immediately on tongue. Tablet dissolves rapidly in saliva; water is not needed. Do not chew, crush, or split tablet.</p></div>
<div class="block meg drugH1Div" id="F7874926"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Remeron, Remeron SolTab: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F020415s038%2C021208s028lbl.pdf%23page%3D23&amp;token=zBFl2l0zAtkd2cG4zZH0fFePakm3cQgPAnEogrK7q2rhfT1vaSBaIrZe%2BkIny8YNVYmr9CtvAJyFj3FnlRXO8QzWyeUUsoIlYk8wozR%2F45QgBjo%2BTKJV%2FNMTY9ZRemgH&amp;TOPIC_ID=9656" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020415s038,021208s028lbl.pdf#page=23</a></p></div>
<div class="block use drugH1Div" id="F197087"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Major depressive disorder (unipolar):</b> Treatment of unipolar major depressive disorder (MDD) in adults.</p></div>
<div class="block off-label drugH1Div" id="F51634622"><span class="drugH1">Use: Off-Label: Adult</span><p>Headache, chronic tension-type, prophylaxis; Panic disorder</p></div>
<div class="block mst drugH1Div" id="F197147"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Remeron may be confused with Premarin, ramelteon, Rozerem, Zemuron</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Mirtazapine is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Avanza [Australia] may be confused with Albenza brand name for albendazole [US]; Avandia brand name for rosiglitazone [US, Canada, and multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Remeron [US, Canada, and multiple international markets] may be confused with Reneuron which is a brand name for fluoxetine [Spain]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F197134"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F197079"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Mirtazapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: Mirtazapine may diminish the antihypertensive effect of Alpha2-Agonists.  Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Mirtazapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Mirtazapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Mirtazapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Serotonergic Non-Opioid CNS Depressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Serotonergic Non-Opioid CNS Depressants may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Mirtazapine may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Mirtazapine.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and for increased mirtazapine toxicities when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Mirtazapine may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): Serotonergic Non-Opioid CNS Depressants may enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Non-Opioid CNS Depressants may enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Mirtazapine may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Mirtazapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: May enhance the CNS depressant effect of Mirtazapine. TraZODone may enhance the serotonergic effect of Mirtazapine. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and CNS depression when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the CNS depressant effect of Serotonergic Non-Opioid CNS Depressants. Tricyclic Antidepressants may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and CNS depression when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Mirtazapine may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54471560"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">If treatment for major depressive disorder is initiated for the first time in females planning a pregnancy, agents other than mirtazapine are preferred (use of mirtazapine is not preferred in pregnant women) (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">The incidence of sexual dysfunction with mirtazapine is generally lower than with selective serotonin reuptake inhibitors (WFSBP [Bauer 2013]).</p></div>
<div class="block pri drugH1Div" id="F197096"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Mirtazapine crosses the placenta (Hatzidaki 2008).</p>
<p style="text-indent:0em;margin-top:2em;">A significant increase in major teratogenic effects has not been observed following exposure to mirtazapine during pregnancy; however, information is limited (CANMAT [MacQueen 2016]; Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated or inadequately treated psychiatric illness may lead to poor compliance with prenatal care. Therapy with antidepressants during pregnancy should be individualized (ACOG 92 2008; CANMAT [MacQueen 2016]). Psychotherapy or other nonmedication therapies may be considered for some women; however, antidepressant medication should be considered for pregnant women with moderate to severe major depressive disorder (MDD) (APA 2010). If treatment for MDD is initiated for the first time during pregnancy, mirtazapine is not recommended (CANMAT [MacQueen 2016]; Larsen 2015; WFSBP [Bauer 2013]); mirtazapine is considered a third-line agent for the treatment of mild to moderate depression during pregnancy (CANMAT [MacQueen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressants is ongoing. Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>
<div class="block brc drugH1Div" id="F6825184"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine and its active metabolite are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The highest relative infant dose (RID) of mirtazapine located in the literature is 4.4%. Authors of the study calculated the RID following maternal administration of mirtazapine 22.5 mg/day to a woman at 6 weeks' postpartum; metabolite concentrations were not evaluated. Breast milk was sampled 4 hours after the maternal dose (Klier 2007). Desmethylmirtazpine can also be detected in breast milk (Kristensen 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine can be detected in the serum of breastfed infants; adverse events have generally not been observed, although possible sedation and weight gain was noted in one case report (Kristensen 2007; Smit 2015; Tonn 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Infants of mothers using psychotropic medications should be monitored daily for changes in sleep, feeding patterns, and behavior (WFSBP [Bauer 2013]) as well as infant growth and neurodevelopment (ABM [Sriraman 2015]; Sachs 2013). When first initiating an antidepressant in a breastfeeding female, agents other than mirtazapine are preferred (Berle 2011; CANMAT [MacQueen 2016]).</p></div>
<div class="block dic drugH1Div" id="F197097"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F197083"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC; renal and hepatic function; lipid profile; weight; suicidality (during the initial 1 to 2 months of therapy or during periods of dosage adjustments).</p></div>
<div class="block pha drugH1Div" id="F197073"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mirtazapine is a tetracyclic antidepressant that works by its central presynaptic alpha<sub>2</sub>-adrenergic antagonist effects, which results in increased release of norepinephrine and serotonin. It is also a potent antagonist of 5-HT<sub>2</sub> and 5-HT<sub>3</sub> serotonin receptors and H<sub>1</sub> histamine receptors and a moderate peripheral alpha<sub>1</sub>-adrenergic and muscarinic antagonist; it does not inhibit the reuptake of norepinephrine or serotonin.</p></div>
<div class="block phk drugH1Div" id="F197091"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Anxiety disorders (panic disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (WFSBP [Bandelow 2023]); some experts suggest up to 12 weeks of treatment may be necessary for response (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~85%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP1A2, 2D6, 3A4 and via demethylation and hydroxylation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~20 to 40 hours; increased with renal or hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (75%) and feces (15%) as metabolites.</p></div>
<div class="block phksp drugH1Div" id="F51159622"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced ~30% in patients with moderate (GFR 11 to 39 mL/minute/1.73 m<sup>2</sup>) and ~50% in patients with severe (GFR &lt;10 mL/minute/1.73 m<sup>2</sup>) kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance decreased by 33% and half-life and serum concentration increased by 39% and 55%, respectively, following a single dose of mirtazapine in elderly patients with mild or moderate hepatic impairment (Mauri 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance is reduced 40% in elderly men and 10% in elderly women.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Women have a longer elimination half-life (37 hours) than men (26 hours).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F197098"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mezeron | Mirtaza | Remeron</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bilanz | Comenter | Eufotina | Farmapina | Noxibel | Remeron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mirtabene | Mirtapel | Mirtaron | Mirtazapin | Mirtazapin actavis | Mirtazapin Bluefish | Mirtazapin G.L. | Mirtazapin teva | Mirtel | Remeron</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo mirtazapine | Apx mirtazapine | Aurozapine | Avanza | Axit | Blooms the chemist mirtazapine | Chemmart Mirtazapine | GenRx Mirtazapine | Milivin | Mirtanza | Mirtazapine an | Mirtazapine arw | Mirtazapine ga | Mirtazapine pfizer | Mirtazapine sandoz | Mirtazon | Noumed mirtazapine | Remeron | Terry White Chemists Mirtazapine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Amiron | Azapin | Mirapin | Mirapro | Mirez | Mirtaz | Mirzalux | Mitaprex | Mitrazin | Rapine | Rejoy</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapine actavis | Mirtazapine apotex | Mirtazapine eg | Mirtazapine merck-generics | Mirtazapine ratiopharm | Mirtazapine sandoz | Mirtazapine teva | Remergon</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirzaten | Mirzaten Q Tab | Remirta</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Menelat | Mirtazapina | Razapina | Remeron | Zapsy</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mirtazap | Mirtazap Mepha | Mirtazapin actavis | Mirtazapin Helvepharm | Mirtazapin Mepha | Mirtazapin Sandoz | Mirtazapin Spirig | Mirtazapin Streuli | Mirtazapin teva | Mirtazapin zentiva | Remeron</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amirel | Ciblex | Divaril | Promyrtil | Promyrtil Soltab | Zuleptan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Kang duo ning | Mi er ning | Pai di sheng | Remeron</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Depreless | Epilfarmo | Mirtapax | Mirtazapina | Mirzalux | Remeron | Tazepin | Zania | Zimvaken</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirtazapin aurovitas | Mirtazapin Bluefish | Mirtazapin orion | Mirtazapin Sandoz | Mirtazapine teva | Mirzaten | Remeron</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Mirta | Mirta tad | Mirtagamma | Mirtalich | Mirtazapin | Mirtazapin 1 A Pharma | Mirtazapin actavis | Mirtazapin al | Mirtazapin ametas | Mirtazapin Aurobindo | Mirtazapin AWD | Mirtazapin Axcount | Mirtazapin Basics | Mirtazapin Beta | Mirtazapin biomo | Mirtazapin Bluefish | Mirtazapin ct | Mirtazapin dura | Mirtazapin Heumann | Mirtazapin Hexal | Mirtazapin Isis | Mirtazapin Neurax | Mirtazapin puren | Mirtazapin Ratiopharm | Mirtazapin Sandoz | Mirtazapin Stada | Mirtazapin teva | Mirtazelon | Mirtazop | Mirtazza | Remergil | Remeron | Zispin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Arintapin | Combar | Mirtazapin gea | Mirtazapin Ratiopharm | Remeron</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Comenter | Menoxis | Mirtafran | Mirtalon | Mirtapin | Mirtaza | Mirtazapina | Mirtazep | Remeron</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ciblex | Mirtapax | Mirtaz | Mirtazapina | Mirzalux | Noxibel | Remeron</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirtastad | Mirtazapin | Mirzaten | Remergil | Remeron</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aprimertaz | Mirpresion | Mirtadepine | Mirtimash | Mirtofutal | Ramizipine | Rapizapine | Remeron | Zapimert</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Afloyan | Mirpik | Mirtamylan | Mirtazapina Actavis | Mirtazapina Almus | Mirtazapina alter | Mirtazapina amneal | Mirtazapina apotex | Mirtazapina Aurobindo | Mirtazapina bayvit | Mirtazapina Bexal | Mirtazapina bluefish pharma | Mirtazapina Cinfa | Mirtazapina combino pharm | Mirtazapina combix | Mirtazapina davur | Mirtazapina flas kern pharma | Mirtazapina merck | Mirtazapina Normon | Mirtazapina Pharmagenus | Mirtazapina Qualigen | Mirtazapina ratiopharm | Mirtazapina rimafar | Mirtazapina sandoz | Mirtazapina Stada | Mirtazapina Tarbis | Mirtazapina Tecnigen | Mirtazapina teva | Mirtazapina ur | Mirtazapina winthrop | Rexer | Rexer Flas | Vastat | Vastat flas</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Arintapin | Miramerck | Mirtachem | Mirtamerck | Mirtaril | Mirtatsapiini ennapharma | Mirtatsapiini Teva | Mirtazapin alpharm | Mirtazapin Bluefish | Mirtazapin generic | Mirtazapin Hexal | Mirtazapin Krka | Mirtazapin Lannacher | Mirtazapin orion | Mirtazapin Ratiopharm | Mirtazapin Sandoz | Mirtazapin teva | Mirtazapine actavis | Mirtazapine Aurobindo | Mirtazon | Remeron</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapine actavis | Mirtazapine Almus | Mirtazapine arrow | Mirtazapine Biogaran | Mirtazapine bluefish | Mirtazapine cristers | Mirtazapine eg | Mirtazapine pfizer | Mirtazapine Qualimed | Mirtazapine Ranbaxy | Mirtazapine ratiopharm | Mirtazapine sandoz | Mirtazapine Zydus | Norset</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapine Almus | Mirtazapine arrow | Mirtazapine cox | Mirtazapine focus | Mirtazapine kent | Mirtazapine pfizer | Zispin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Azapin | Depreram | Mirrador Flash | Mirtamor | Mirtazafer | Mirtazapine/Generics | Mirtazapine/mylan | Motofen | Remeron | Saxib</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mirnite | Mirtazapine teva | Remeron | Remirta</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Calixta | Mirzaten | Mirzaten Q Tab | Odonazin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mirtastad | Mirtawin | Mirtazapin Sandoz | Mirtazapin zentiva | Mirtazapine Aurobindo | Mirtazapine bluefish | Mirtel | Mirzaten | Mirzaten Q Tab | Mizapin | Remeron | Yarocen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Remeron</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mirap | Mirtall | Mirtaz | Mirtazapine bluefish | Mirtazapine teva | Mirzaten | Tazamel | Zismirt | Zispin | Zispin soltab</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Miro | Mirtazapine teva | Remeron</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">M zap | Matiz | Maz | Mira | Miramind | Miraz | Mirazep | Mirdep | Mirfast | Mirnite | Mirsol | Mirt | Mirtadep | Mirtakem | Mirtalite | Mirtasure md | Mirtaz | Mirtee | Mirtex | Mirza | Mirzest | Mitapin | Mitocent | Mitpin | Mitraford | Mitrazac | Mizhra | Mompress | Mtz | Nasdep | Nutaz | Orzap | Tezepin | Zipdep</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Miron</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapina | Mirtazapina Actavis | Mirtazapina Almus | Mirtazapina Aurobindo | Mirtazapina blu | Mirtazapina Doc | Mirtazapina eg | Mirtazapina krka | Mirtazapina merck | Mirtazapina ratiopharm | Mirtazapina sandoz | Mirtazapina sandoz gmbh | Mirtazapina winthrop | Remeron | Zatimar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Dinertone | Remeron</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapine ee | Mirtazapine kyorin | Mirtazapine kyosomirai | Mirtazapine nipro | Mirtazapine nissin | Mirtazapine od | Mirtazapine od dsep | Mirtazapine od towa | Mirtazapine pfizer | Mirtazapine takeda teva | Reflex | Remeron</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Menelat | Mezeron | Mirtaz</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Milta | Milta od | Mirta | Mirta od | Mirtapin | Mirtax | Mirzentac | Multapine | Pharmascience mirtazapine | Remeron | Remeron soltab | Remixil | Teva mirtazapine odt | Yungjin mirtazapine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Mirtaza | Remeron</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mirta | Remeron</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirtastad | Mirtazapin | Mirtazapin actavis | Mirtazapin orion | Mirtazapine Aurobindo | Mirtazepine Teva | Mirzaten | Remeron | Valdren</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docmirtazapine | Mirtazapin Ratiopharm | Mirtazapine eg | Remergon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirtastad | Mirtazapin Ratiopharm | Mirtazapine Aurobindo | Mirtel | Mirzaten | Mirzaten Q Tab | Remeron | Valdren</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Remeron</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alpreak | Comenter | Conalpin | Mirtazapina | Ociples | Ociplos | Remeron | Remeron soltab | Segmir | Zapex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Menelat | Remeron</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapine A | Mirtazapine actavis | Mirtazapine Alpharma | Mirtazapine Aurobindo | Mirzasna | Remeron</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapin | Mirtazapin Arrow | Mirtazapin Bluefish | Mirtazapin Hexal | Mirtazapin orion | Mirtazapin teva | Mirtazapine Aurobindo | Remeron</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo mirtazapine | Avanza | Noumed mirtazapine | Remeron</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ciblex | Deprezapina | Exania | Midexar | Mirtalab | Mirtapax | Mirtavitae | Mirtaz | Mirtazapina | Noxibel | Remedrint | Remeron</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Menelat | Mirazep | Remeron</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Actizipine | Elaxine | Jeta | M. tazapine | Mazipine | Mipine | Mirtaget | Mirtanel | Mirtasat | Mirtawin | Mirtazameron | Mirtazep | Mzapine | Nassa | Notense | Ramargon | Remeron | Remirta | Rezam | Sypine | Tazip | Tizapine | Valta | Zapmir | Zemer | Zipdep</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirtagen | Mirtastad | Mirtazapine bluefish | Mirtazapine teva | Mirzaten | Mirzaten Q Tab | Remeron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Remeron</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mirtaz | Mirtazapina | Mirtazapina Almus | Mirtazapina Aurobindo | Mirtazapina aurovitas | Mirtazapina Ciclum | Mirtazapina Germed | Mirtazapina krka | Mirtazapina ritisca | Mirtazapina sandoz | Mirtazapina wynn | Psidep | Remeron</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ciblex | Contrelmin | Mirtapax | Noxibel</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mirtaz | Remeron | Remeron Soltab</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirtazapine teva | Mirzaten | Mirzaten Q Tab | Remeron | Valdren | Zulin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Calixta | Esprital | Mirtalan | Mirtazapine canon | Mirtazonal | Mirzaten | Mirzaten Q Tab | Noxibel | Remeron</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo mirtazapine | Mirtaza | Mirzagen | Pms-mirtazapine | Remeron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapin 2care4 | Mirtazapin abacus medicine | Mirtazapin actavis | Mirtazapin Alpharma | Mirtazapin Alternova | Mirtazapin Arrow | Mirtazapin Aurobindo | Mirtazapin Bluefish | Mirtazapin ebb | Mirtazapin Ethypharm | Mirtazapin Hexal | Mirtazapin Imi Pharma | Mirtazapin Krka | Mirtazapin Mylan | Mirtazapin orion | Mirtazapin Ratiopharm | Mirtazapin Sandoz | Mirtazapin Stada | Mirtazapin teva | Mirtin | Remeron | Trimazimyl</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo mirtazapine | Mirtazapine sandoz | Remeron</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mirtazapin Mylan | Mirzaten | Remeron</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Calixta | Esprital | Mirtazapine bluefish | Mirtazapine teva | Mirzaten | Mirzaten Q Tab | Remeron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Remeron | Zamir 15 | Zamir 30 | Zymron</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Minelza | Redepra | Remeron | Velorin OD | Zestat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apa mirtazapine | Minivane | Mirtan | Mirtapine | Mirtazapine sandoz | Mirtine | Pms-mirtazapine | Remeron | Sinmaron | Smilon | U Mirtaron | U-Zepine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Esprital | Mirazep | Mirtastadin | Mirtazapin | Mirtazapine odt | Mirtel | Remeron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mizapin | Noxibel | Remeron | Terladep</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Comenter | Mirtazapina | Mirtazaval | Mirtazpen | Remeron</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Itazpam</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">ADCO Mirteron | Auro mirtazapine | Miradep | Mytra | Ramure | Remeron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29694944">
<a name="29694944"></a>Abou Kassm S, Naja W. Looking for bipolarity in antidepressant discontinuation manic states: update and diagnostic considerations of the phenomenon. <i>J Affect Disord</i>. 2018;235:551-556. doi:10.1016/j.jad.2018.04.080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29694944/pubmed" id="29694944" target="_blank">29694944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins--Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation," <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12165012">
<a name="12165012"></a>Ahmed A. Neutropenia associated with mirtazapine use: is a drop in the neutrophil count in a symptomatic older adults a cause for concern?. <i>J Am Geriatr Soc</i>. 2002;50(8):1461-1463. doi:10.1046/j.1532-5415.2002.50375.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12165012/pubmed" id="12165012" target="_blank">12165012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12776393">
<a name="12776393"></a>Ali S, Milev R. Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature. <i>Can J Psychiatry</i>. 2003;48(4):258-264. doi:10.1177/070674370304800410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12776393/pubmed" id="12776393" target="_blank">12776393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed December 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24977717">
<a name="24977717"></a>Ansermot N, Hodel PF, Eap CB. Serotonin toxicity after addition of mirtazapine to escitalopram. <i>J Clin Psychopharmacol</i>. 2014;34(4):540-541. doi:10.1097/JCP.0000000000000170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/24977717/pubmed" id="24977717" target="_blank">24977717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11607047">
<a name="11607047"></a>Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. <i>CNS Drug Rev</i>. 2001;7(3):249-264. doi:10.1111/j.1527-3458.2001.tb00198.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11607047/pubmed" id="11607047" target="_blank">11607047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23121994">
<a name="23121994"></a>Arnold DM, Kukaswadia S, Nazi I, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. <i>J Thromb Haemost</i>. 2013a;11(1):169-176. doi:10.1111/jth.12052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23121994/pubmed" id="23121994" target="_blank">23121994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23845922">
<a name="23845922"></a>Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. <i>Transfus Med Rev</i>. 2013b;27(3):137-145. doi:10.1016/j.tmrv.2013.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23845922/pubmed" id="23845922" target="_blank">23845922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21519537">
<a name="21519537"></a>Atmaca M, Korkmaz S, Topuz M, Mermi O. Mirtazapine augmentation for selective serotonin reuptake inhibitor-induced sexual dysfunction: a retrospective investigation. <i>Psychiatry Investig</i>. 2011;8(1):55-57. doi:10.4306/pi.2011.8.1.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/21519537/pubmed" id="21519537" target="_blank">21519537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30504360">
<a name="30504360"></a>Bakchoul T, Marini I. Drug-associated thrombocytopenia. <i>Hematology Am Soc Hematol Educ Program</i>. 2018;2018(1):576-583. doi:10.1182/asheducation-2018.1.576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/30504360/pubmed" id="30504360" target="_blank">30504360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20739826">
<a name="20739826"></a>Balaz M, Rektor I. Gradual onset of dyskinesia induced by mirtazapine. <i>Neurol India</i>. 2010;58(4):672-673. doi:10.4103/0028-3886.68693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/20739826/pubmed" id="20739826" target="_blank">20739826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.<i> J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-Induced Serotonin Syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21692606">
<a name="21692606"></a>Basavraj V, Nanjundappa GB, Chandra PS. Mirtazapine induced mania in a woman with major depression in the absence of features of bipolarity. <i>Aust N Z J Psychiatry</i>. 2011;45(10):901. doi:10.3109/00048674.2011.589369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/21692606/pubmed" id="21692606" target="_blank">21692606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385. doi:10.3109/15622975.2013.804195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry.</i> 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653542">
<a name="9653542"></a>Benazzi F. Mirtazapine withdrawal symptoms. <i>Can J Psychiatry</i>. 1998;43(5):525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/9653542/pubmed" id="9653542" target="_blank">9653542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9695042">
<a name="9695042"></a>Benazzi F. Serotonin syndrome with mirtazapine-fluoxetine combination. <i>Int J Geriatr Psychiatry</i>. 1998;13(7):495-496. doi:10.1002/(sici)1099-1166(199807)13:7&lt;495::aid-gps803&gt;3.0.co;2-i<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/9695042/pubmed" id="9695042" target="_blank">9695042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15159466">
<a name="15159466"></a>Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. <i>Neurology</i>. 2004;62(10):1706-1711.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15159466/pubmed" id="15159466" target="_blank">15159466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20482606">
<a name="20482606"></a>Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J; EFNS. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. <i>Eur J Neurol.</i> 2010;17(11):1318-1325. doi:10.1111/j.1468-1331.2010.03070.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/20482606/pubmed" id="20482606" target="_blank">20482606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014614">
<a name="15014614"></a>Berigan TR. Mirtazapine-associated withdrawal symptoms: a case report. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(3):143. doi:10.4088/pcc.v03n0307a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15014614/pubmed" id="15014614" target="_blank">15014614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22299006">
<a name="22299006"></a>Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/22299006/pubmed" id="22299006" target="_blank">22299006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24228948">
<a name="24228948"></a>Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. <i>Clin Toxicol (Phila).</i> 2014;52(1):20-24. doi:10.3109/15563650.2013.859264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/24228948/pubmed" id="24228948" target="_blank">24228948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12409687">
<a name="12409687"></a>Bhanji NH, Margolese HC, Saint-Laurent M, Chouinard G. Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'?. <i>Int Clin Psychopharmacol</i>. 2002;17(6):319-322. doi:10.1097/00004850-200211000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12409687/pubmed" id="12409687" target="_blank">12409687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12680749">
<a name="12680749"></a>Biswas PN, Wilton LV, Shakir SA. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. <i>J Psychopharmacol</i>. 2003;17(1):121-126. doi:10.1177/0269881103017001716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12680749/pubmed" id="12680749" target="_blank">12680749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11712626">
<a name="11712626"></a>Boshuisen ML, Slaap BR, Vester-Blokland ED, den Boer JA. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. <i>Int Clin Psychopharmacol.</i> 2001;16(6):363-368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11712626/pubmed" id="11712626" target="_blank">11712626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29486665">
<a name="29486665"></a>Bowers RD, Valanejad SM, Holombo AA. Mirtazapine-induced pancreatitis-a case report. <i>J Pharm Pract</i>. 2019;32(5):586-588. doi:10.1177/0897190018760645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29486665/pubmed" id="29486665" target="_blank">29486665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10431683">
<a name="10431683"></a>Boyarsky BK, Haque W, Rouleau MR, Hirschfeld RM. Sexual functioning in depressed outpatients taking mirtazapine. <i>Depress Anxiety</i>. 1999;9(4):175-179. doi:10.1002/(sici)1520-6394(1999)9:4&lt;175::aid-da5&gt;3.0.co;2-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/10431683/pubmed" id="10431683" target="_blank">10431683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome [published correction appears in <i>N Engl J Med</i>. 2007;356(23):2437] [published correction appears in <i>N Engl J Med</i>. 2009;361(17):1714]. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21894129">
<a name="21894129"></a>Butler S, Holt C, Agius M, Zaman R. An audit to compare the efficacy of treatment (as indicated by discharge rates and reduction in suicidality) among patients with refractory depression in a Bedfordshire Community Mental Health Team receiving augmentation therapy with either mirtazepine or atypical antipsychotics. <i>Psychiatr Danub</i>. 2011;23 Suppl 1:S171-S174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/21894129/pubmed" id="21894129" target="_blank">21894129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12090820">
<a name="12090820"></a>Carli V, Sarchiapone M, Camardese G, Roman L, DeRisio S. Mirtazapine in the treatment of panic disorder. <i>Arch Gen Psychiatry.</i> 2002;59(7):661-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12090820/pubmed" id="12090820" target="_blank">12090820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12885107">
<a name="12885107"></a>Chen JL, Spinowitz N, Karwa M. Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. <i>Pharmacotherapy</i>. 2003;23(7):940-944. doi:10.1592/phco.23.7.940.32725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12885107/pubmed" id="12885107" target="_blank">12885107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21304130">
<a name="21304130"></a>Chiu HW, Li TC. Rapid weight gain during mirtazapine treatment. <i>J Neuropsychiatry Clin Neurosci</i>. 2011;23(1):E7. doi:10.1176/jnp.23.1.jnpe7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/21304130/pubmed" id="21304130" target="_blank">21304130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19567774">
<a name="19567774"></a>Civalier KA, Krahn LE, Agrwal N. Repeated episodes of neutropenia triggered by mirtazapine. <i>Psychosomatics</i>. 2009;50(3):299-300. doi:10.1176/appi.psy.50.3.299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19567774/pubmed" id="19567774" target="_blank">19567774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cosci.2017">
<a name="Cosci.2017"></a>Cosci F. Withdrawal symptoms after discontinuation of a noradrenergic and specific serotonergic antidepressant: a case report and review of the literature. <i>Personalized Medicine in Psychiatry</i>. 2017;1-2:81-84. doi:10.1016/j.pmip.2016.11.001</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19364298">
<a name="19364298"></a>Coskun M, Karakoc S, Kircelli F, Mukaddes NM. Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. <i>J Child Adolesc Psychopharmacol</i>. 2009;19(2):203-206. doi:10.1089/cap.2008.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19364298/pubmed" id="19364298" target="_blank">19364298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25693810">
<a name="25693810"></a>Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. <i>BMJ</i>. 2015;350:h517. doi:10.1136/bmj.h517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25693810/pubmed" id="25693810" target="_blank">25693810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22752315">
<a name="22752315"></a>Decoutere L, De Winter S, Vander Weyden L, et al. A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge [published correction appears in <i>Int J Clin Pharm</i>. 2012;34(5):689]. <i>Int J Clin Pharm</i>. 2012;34(5):686-688. doi:10.1007/s11096-012-9666-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/22752315/pubmed" id="22752315" target="_blank">22752315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21057250">
<a name="21057250"></a>Dholakia R, Schleifer SJ, Ahmad YJ, Narang IS. Delayed-onset mirtazapine-related leukopenia and rechallenge. <i>J Clin Psychopharmacol</i>. 2010;30(6):758. doi:10.1097/JCP.0b013e3181faa564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/21057250/pubmed" id="21057250" target="_blank">21057250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16965209">
<a name="16965209"></a>Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. <i>J Clin Psychiatry</i>. 2006;67(8):1280-1284. doi:10.4088/jcp.v67n0817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16965209/pubmed" id="16965209" target="_blank">16965209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26629801">
<a name="26629801"></a>Duncan NA, Clifford KM, Shvarts OM. Mirtazapine-associated hypertriglyceridemia and hyperglycemia. <i>Consult Pharm</i>. 2015;30(11):657-663. doi:10.4140/TCP.n.2015.657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26629801/pubmed" id="26629801" target="_blank">26629801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19321030">
<a name="19321030"></a>Einarson A, Choi J, Einarson TR, et al, "Incidence of Major Malformations in Infants Following Antidepressant Exposure in Pregnancy: Results of a large Prospective Cohort Study," <i>Can J Psychiatry</i>, 2009, 54(4):242-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19321030/pubmed" id="19321030" target="_blank">19321030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24926846">
<a name="24926846"></a>Fauchère PA. Recurrent, persisting panic attacks after sudden discontinuation of mirtazapine treatment: a case report. <i>Int J Psychiatry Clin Pract</i>. 2004;8(2):127-129. doi:10.1080/13651500410006134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/24926846/pubmed" id="24926846" target="_blank">24926846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683858">
<a name="16683858"></a>Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16683858/pubmed" id="16683858" target="_blank">16683858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17785222">
<a name="17785222"></a>Fernandez A, Bang SE, Srivathsan K, Vieweg WV. Cardiovascular side effects of newer antidepressants. <i>Anadolu Kardiyol Derg</i>. 2007;7(3):305-309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/17785222/pubmed" id="17785222" target="_blank">17785222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23 Suppl 1:27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29734995">
<a name="29734995"></a>Gandotra K, Chen P, Jaskiw GE, Konicki PE, Strohl KP. Effective treatment of insomnia with mirtazapine attenuates concomitant suicidal ideation. <i>J Clin Sleep Med</i>. 2018;14(5):901-902. doi:10.5664/jcsm.7142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29734995/pubmed" id="29734995" target="_blank">29734995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32383050">
<a name="32383050"></a>Gholyaf M, Sheikh V, Yasrebifar F, Mohammadi Y, Mirjalili M, Mehrpooya M. Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study. <i>Int Urol Nephrol</i>. 2020;52(6):1155-1165. doi:10.1007/s11255-020-02473-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/32383050/pubmed" id="32383050" target="_blank">32383050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33022115">
<a name="33022115"></a>Gill H, Gill B, El-Halabi S, et al. Antidepressant medications and weight change: a narrative review. <i>Obesity (Silver Spring)</i>. 2020;28(11):2064-2072. doi:10.1002/oby.22969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/33022115/pubmed" id="33022115" target="_blank">33022115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16342227">
<a name="16342227"></a>Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. <i>Hum Psychopharmacol</i>. 2006;21(2):117-125. doi:10.1002/hup.750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16342227/pubmed" id="16342227" target="_blank">16342227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14646604">
<a name="14646604"></a>Gillman PK. Mirtazapine: unable to induce serotonin toxicity? <i>Clin Neuropharmacol</i>. 2003;26(6):288-290. doi:10.1097/00002826-200311000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/14646604/pubmed" id="14646604" target="_blank">14646604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11999246">
<a name="11999246"></a>Girishchandra BG, Johnson L, Cresp RM, Orr KG. Mirtazapine-induced akathisia. <i>Med J Aust</i>. 2002;176(5):242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11999246/pubmed" id="11999246" target="_blank">11999246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16005413">
<a name="16005413"></a>Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? <i>J Am Med Dir Assoc</i>. 2005;6(4):265-269. doi:10.1016/j.jamda.2005.04.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16005413/pubmed" id="16005413" target="_blank">16005413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10446735">
<a name="10446735"></a>Gorman JM. Mirtazapine: clinical overview. <i>J Clin Psychiatry</i>. 1999;60 Suppl 17:9-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/10446735/pubmed" id="10446735" target="_blank">10446735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243609">
<a name="12243609"></a>Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. <i>Ann Pharmacother</i>. 2002;36(10):1577-1589. doi:10.1345/aph.1A195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12243609/pubmed" id="12243609" target="_blank">12243609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2-58. doi:10.1080/15622975.2017.1384850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18626283">
<a name="18626283"></a>Gulsun M, Doruk A. Mirtazapine-induced akathisia. <i>J Clin Psychopharmacol</i>. 2008;28(4):467. doi:10.1097/JCP.0b013e31817ed22c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18626283/pubmed" id="18626283" target="_blank">18626283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hatzidaki.1">
<a name="Hatzidaki.1"></a>Hatzidaki E, Toutoudaki M, Christaki, et al. A non-fatal suicide attempt of a pregnant woman using mirtazapine and venlafaxine. <i>Toxicol Lett.</i> 2008;180(suppl):S141-S142.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30626746">
<a name="30626746"></a>Hennings JM, Heel S, Lechner K, et al. Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men. <i>JCI Insight</i>. 2019;4(1):e123786. doi:10.1172/jci.insight.123786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/30626746/pubmed" id="30626746" target="_blank">30626746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11918514">
<a name="11918514"></a>Hernández JL, Ramos FJ, Infante J, Rebollo M, González-Macías J. Severe serotonin syndrome induced by mirtazapine monotherapy. <i>Ann Pharmacother</i>. 2002;36(4):641-643. doi:10.1345/aph.1A302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11918514/pubmed" id="11918514" target="_blank">11918514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16373922">
<a name="16373922"></a>Himmerich H, Fulda S, Schaaf L, Beitinger PA, Schuld A, Pollmächer T. Changes in weight and glucose tolerance during treatment with mirtazapine. <i>Diabetes Care</i>. 2006;29(1):170. doi:10.2337/diacare.29.1.170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16373922/pubmed" id="16373922" target="_blank">16373922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019">
<a name="Hirsch.2019"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com.</a> Accessed June 28, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com.</a> Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14970364">
<a name="14970364"></a>Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. <i>Ann Pharmacother</i>. 2004;38(3):411-413. doi:10.1345/aph.1D344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/14970364/pubmed" id="14970364" target="_blank">14970364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12192206">
<a name="12192206"></a>Hui CK, Yuen MF, Wong WM, Lam SK, Lai CL. Mirtazapine-induced hepatotoxicity. <i>J Clin Gastroenterol</i>. 2002;35(3):270-271. doi:10.1097/00004836-200209000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12192206/pubmed" id="12192206" target="_blank">12192206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30985094">
<a name="30985094"></a>Hutchins D, Hall J, Sharma A. Mirtazapine-induced transient dyskinesia. <i>Prim Care Companion CNS Disord</i>. 2019;21(2):18l02377. doi:10.4088/PCC.18l02377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/30985094/pubmed" id="30985094" target="_blank">30985094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11555082">
<a name="11555082"></a>Hutchison LC. Mirtazapine and bone marrow suppression: a case report. <i>J Am Geriatr Soc</i>. 2001;49(8):1129-1130. doi:10.1046/j.1532-5415.2001.49224.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11555082/pubmed" id="11555082" target="_blank">11555082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14646603">
<a name="14646603"></a>Isbister GK, Whyte IM. Adverse reactions to mirtazapine are unlikely to be serotonin toxicity. <i>Clin Neuropharmacol</i>. 2003;26(6):287-290. doi:10.1097/00002826-200311000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/14646603/pubmed" id="14646603" target="_blank">14646603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813948">
<a name="23813948"></a>Iwamoto K, Kawano N, Sasada K, et al. Effects of low-dose mirtazapine on driving performance in healthy volunteers. <i>Hum Psychopharmacol</i>. 2013;28(5):523-528. doi:10.1002/hup.2327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23813948/pubmed" id="23813948" target="_blank">23813948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28093029">
<a name="28093029"></a>Karsten J, Hagenauw LA, Kamphuis J, Lancel M. Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial. <i>J Psychopharmacol</i>. 2017;31(3):327-337. doi:10.1177/0269881116681399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/28093029/pubmed" id="28093029" target="_blank">28093029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20146649">
<a name="20146649"></a>Kasper S, Montgomery SA, Möller HJ, et al. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. <i>World J Biol Psychiatry</i>. 2010;11(1):36-44. doi:10.3109/15622970701691503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/20146649/pubmed" id="20146649" target="_blank">20146649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9352961">
<a name="9352961"></a>Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression [published correction appears in <i>Drug Saf</i>. 1998;18(2):123]. <i>Drug Saf</i>. 1997;17(4):251-264. doi:10.2165/00002018-199717040-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/9352961/pubmed" id="9352961" target="_blank">9352961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34326284">
<a name="34326284"></a>Keshtkarjahromi M, Mariscal J, Dempsey K, Tonarelli S. Treatment of severe excoriation disorder with mirtazapine: a case report. <i>Clin Neuropharmacol</i>. 2021;44(5):189-190. doi:10.1097/WNF.0000000000000467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/34326284/pubmed" id="34326284" target="_blank">34326284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15187213">
<a name="15187213"></a>Khandat AB, Nurnberger JI Jr, Shekhar A. Possible mirtazapine-induced rhabdomyolysis. <i>Ann Pharmacother</i>. 2004;38(7-8):1321. doi:10.1345/aph.1D487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15187213/pubmed" id="15187213" target="_blank">15187213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12713682">
<a name="12713682"></a>Khawaja IS, Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. <i>Heart Dis</i>. 2003;5(2):153-160. doi:10.1097/01.hdx.0000061695.97215.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12713682/pubmed" id="12713682" target="_blank">12713682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18756499">
<a name="18756499"></a>Kim SW, Shin IS, Kim JM, Park KH, Youn T, Yoon JS. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. <i>Hum Psychopharmacol</i>. 2008;23(7):615-620. doi:10.1002/hup.965<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18756499/pubmed" id="18756499" target="_blank">18756499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17267804">
<a name="17267804"></a>Klier CM, Mossaheb N, Lee A, et al, "Mirtazapine and Breastfeeding: Maternal and Infant Plasma Levels," <i>Am J Psychiatry</i>, 2007, 164(2):348-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/17267804/pubmed" id="17267804" target="_blank">17267804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28822709">
<a name="28822709"></a>Kolla BP, Mansukhani MP, Bostwick JM. The influence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review. <i>Sleep Med Rev</i>. 2018;38:131-140. doi:10.1016/j.smrv.2017.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/28822709/pubmed" id="28822709" target="_blank">28822709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15732128">
<a name="15732128"></a>Konitsiotis S, Pappa S, Mantas C, Mavreas V. Acute reversible dyskinesia induced by mirtazapine. <i>Mov Disord</i>. 2005;20(6):771. doi:10.1002/mds.20432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15732128/pubmed" id="15732128" target="_blank">15732128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12518269">
<a name="12518269"></a>Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. <i>Pharmacopsychiatry</i>. 2002;35(6):220-225. doi:10.1055/s-2002-36390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12518269/pubmed" id="12518269" target="_blank">12518269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16970569">
<a name="16970569"></a>Kristensen JH, Ilett KF, Rampono J, et al, "Transfer of the Antidepressant Mirtazapine Into Breast Milk," <i>Br J Clin Pharmacol</i>, 2007, 63(3):322-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16970569/pubmed" id="16970569" target="_blank">16970569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16649829">
<a name="16649829"></a>Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. <i>J Clin Psychiatry</i>. 2006;67(3):421-424. doi:10.4088/jcp.v67n0313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16649829/pubmed" id="16649829" target="_blank">16649829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28940138">
<a name="28940138"></a>Leach MJ, Pratt NL, Roughead EE. The risk of hip fracture due to mirtazapine exposure when switching antidepressants or using other antidepressants as add-on therapy. <i>Drugs Real World Outcomes</i>. 2017;4(4):247-255. doi:10.1007/s40801-017-0120-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/28940138/pubmed" id="28940138" target="_blank">28940138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20396434">
<a name="20396434"></a>Lee KU, Lee YM, Nam JM, et al. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. <i>Psychiatry Investig</i>. 2010;7(1):55-59. doi:10.4306/pi.2010.7.1.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/20396434/pubmed" id="20396434" target="_blank">20396434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18004128">
<a name="18004128"></a>Lennestål R and Källén B, "Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants," <i>J Clin Psychopharmacol</i>, 2007, 27(6):607-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18004128/pubmed" id="18004128" target="_blank">18004128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12737939">
<a name="12737939"></a>Liu X, Sahud MA. Glycoprotein IIb/IIIa complex is the target in mirtazapine-induced immune thrombocytopenia. <i>Blood Cells Mol Dis</i>. 2003;30(3):241-245. doi:10.1016/s1079-9796(03)00037-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12737939/pubmed" id="12737939" target="_blank">12737939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10789310">
<a name="10789310"></a>MacCall C, Callender J. Mirtazapine withdrawal causing hypomania. <i>Br J Psychiatry</i>. 1999;175:390. doi:10.1192/bjp.175.4.390a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/10789310/pubmed" id="10789310" target="_blank">10789310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37055872">
<a name="37055872"></a>Maidwell-Smith A, Kirk C. Mirtazapine-induced neutropenic sepsis in an older person: a case report. <i>J Med Case Rep</i>. 2023;17(1):163. doi:10.1186/s13256-023-03881-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/37055872/pubmed" id="37055872" target="_blank">37055872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25716506">
<a name="25716506"></a>Makiguchi A, Nishida M, Shioda K, Suda S, Nisijima K, Kato S. Mirtazapine-induced restless legs syndrome treated with pramipexole. <i>J Neuropsychiatry Clin Neurosci</i>. 2015;27(1):e76. doi:10.1176/appi.neuropsych.13120357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25716506/pubmed" id="25716506" target="_blank">25716506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124786">
<a name="20124786"></a>Markoula S, Konitsiotis S, Chatzistefanidis D, Lagos G, Kyritsis AP. Akathisia induced by mirtazapine after 20 years of continuous treatment. <i>Clin Neuropharmacol</i>. 2010;33(1):50-51. doi:10.1097/WNF.0b013e3181bf213b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/20124786/pubmed" id="20124786" target="_blank">20124786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31975466">
<a name="31975466"></a>Matsuda Y, Furukawa Y, Yamazaki R, et al. Mirtazapine-induced long QT syndrome in an elderly patient: a case report. <i>Psychogeriatrics</i>. 2020;20(4):536-537. doi:10.1111/psyg.12520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/31975466/pubmed" id="31975466" target="_blank">31975466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32547158">
<a name="32547158"></a>Mehrpooya M, Gholyaf M, Yasrebifar F, Mohammadi Y, Sheikh V. Evaluation of efficacy of mirtazapine on pruritus and serum histamine and serotonin levels in patients undergoing hemodialysis: a before-after pilot clinical trial. <i>Int J Nephrol Renovasc Dis</i>. 2020;13:129-138. doi:10.2147/IJNRD.S246393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/32547158/pubmed" id="32547158" target="_blank">32547158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29472752">
<a name="29472752"></a>Menon V, Madhavapuri P. Low-dose mirtazapine-induced nightmares necessitating its discontinuation in a young adult female. <i>J Pharmacol Pharmacother</i>. 2017;8(4):182-184. doi:10.4103/jpp.JPP_116_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29472752/pubmed" id="29472752" target="_blank">29472752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mirtazapine.1">
<a name="Mirtazapine.1"></a>Mirtazapine tablets [prescribing information]. Weston, FL: Apotex Corp; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24930788">
<a name="24930788"></a>Montañés-Rada F, De Lucas-Taracena MT, Sánchez-Romero S. Mirtazapine versus paroxetine in panic disorder: an open study. <i>Int J Psychiatry Clin Pract.</i> 2005;9(2):87-93. doi:10.1080/13651500510018248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/24930788/pubmed" id="24930788" target="_blank">24930788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859791">
<a name="22859791"></a>Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). <i>Nephrol Dial Transplant</i>. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/22859791/pubmed" id="22859791" target="_blank">22859791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21453380">
<a name="21453380"></a>Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. <i>J Am Geriatr Soc</i>. 2011;59(4):577-585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/21453380/pubmed" id="21453380" target="_blank">21453380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12927002">
<a name="12927002"></a>Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. The effects of mirtazapine on plasma lipid profiles in healthy subjects. <i>J Clin Psychiatry</i>. 2003;64(8):883-889. doi:10.4088/jcp.v64n0805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12927002/pubmed" id="12927002" target="_blank">12927002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23055861">
<a name="23055861"></a>Novak KJ, Douglas WI, Kuhn RJ. Hypotension following cardiac surgery associated with paroxetine and mirtazapine withdrawal. <i>J Pediatr Pharmacol Ther</i>. 2008;13(1):25-28. doi:10.5863/1551-6776-13.1.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23055861/pubmed" id="23055861" target="_blank">23055861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9265949">
<a name="9265949"></a>Nutt D. Mirtazapine: pharmacology in relation to adverse effects. <i>Acta Psychiatr Scand Suppl</i>. 1997;391:31-37. doi:10.1111/j.1600-0447.1997.tb05956.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/9265949/pubmed" id="9265949" target="_blank">9265949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12404669">
<a name="12404669"></a>Nutt DJ. Tolerability and safety aspects of mirtazapine. <i>Hum Psychopharmacol</i>. 2002;17 Suppl 1:S37-S41. doi:10.1002/hup.388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12404669/pubmed" id="12404669" target="_blank">12404669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract</i>. 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29626184">
<a name="29626184"></a>Papazisis G, Siafis S, Tzachanis D. Tachyphylaxis to the sedative action of mirtazapine. <i>Am J Case Rep</i>. 2018;19:410-412. doi:10.12659/ajcr.908412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29626184/pubmed" id="29626184" target="_blank">29626184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29472753">
<a name="29472753"></a>Pombo R, Johnson E, Gamboa A, Omalu B. Autopsy-proven mirtazapine withdrawal-induced mania/hypomania associated with sudden death. <i>J Pharmacol Pharmacother</i>. 2017;8(4):185-187. doi:10.4103/jpp.JPP_162_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29472753/pubmed" id="29472753" target="_blank">29472753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16497273">
<a name="16497273"></a>Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. <i>Biol Psychiatry</i>. 2006;59(11):1071-1077. doi:10.1016/j.biopsych.2005.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/16497273/pubmed" id="16497273" target="_blank">16497273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26557987">
<a name="26557987"></a>Praharaj SK, Kongasseri S, Behere RV, Sharma PS. Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>Ther Adv Psychopharmacol</i>. 2015;5(5):307-313. doi:10.1177/2045125315601343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26557987/pubmed" id="26557987" target="_blank">26557987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11001237">
<a name="11001237"></a>Radhakishun FS, van den Bos J, van der Heijden BC, Roes KC, O'Hanlon JF. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. <i>J Clin Psychopharmacol</i>. 2000;20(5):531-537. doi:10.1097/00004714-200010000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11001237/pubmed" id="11001237" target="_blank">11001237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18649586">
<a name="18649586"></a>Raymond CB, Wazny LD, Honcharik PL. Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease. <i>Nephrol</i>
<i>Nurs J</i>. 2008;35(3):257-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18649586/pubmed" id="18649586" target="_blank">18649586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26702190">
<a name="26702190"></a>Raveendranathan D, Swaminath GR. Mirtazapine induced akathisia: understanding a complex mechanism. <i>Indian J Psychol Med</i>. 2015;37(4):474-475. doi:10.4103/0253-7176.168615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26702190/pubmed" id="26702190" target="_blank">26702190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Remeron.1">
<a name="Remeron.1"></a>Remeron (mirtazapine) [prescribing information]. Jersey City, NJ: Organon USA LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Remeron.2">
<a name="Remeron.2"></a>Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RemeronSolTab.1">
<a name="RemeronSolTab.1"></a>Remeron SolTab (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32546134">
<a name="32546134"></a>Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. <i>BMC Psychiatry</i>. 2020;20(1):308. doi:10.1186/s12888-020-02711-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/32546134/pubmed" id="32546134" target="_blank">32546134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11593305">
<a name="11593305"></a>Ribeiro L, Busnello JV, Kauer-Sant'Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. <i>Braz J Med Biol Res.</i> 2001;34(10):1303-1307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11593305/pubmed" id="11593305" target="_blank">11593305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee on Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27593622">
<a name="27593622"></a>Salvi V, Mencacci C, Barone-Adesi F. H1-histamine receptor affinity predicts weight gain with antidepressants. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1673-1677. doi:10.1016/j.euroneuro.2016.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/27593622/pubmed" id="27593622" target="_blank">27593622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490773">
<a name="12490773"></a>Sarchiapone M, Amore M, De Risio S, et al. Mirtazapine in the treatment of panic disorder: an open-label trial.<i> Int Clin Psychopharmacol.</i> 2003;18(1):35-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12490773/pubmed" id="12490773" target="_blank">12490773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19440080">
<a name="19440080"></a>Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. <i>J Clin Psychopharmacol</i>. 2009;29(3):259-266. doi:10.1097/JCP.0b013e3181a5233f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19440080/pubmed" id="19440080" target="_blank">19440080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21062615">
<a name="21062615"></a>Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. <i>J Clin Psychiatry</i>. 2010;71(10):1259-1272. doi:10.4088/JCP.09r05346blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/21062615/pubmed" id="21062615" target="_blank">21062615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30344142">
<a name="30344142"></a>Shinith D, Mathilakath A, Kim DI, Patel B. Sleep-related eating disorder with mirtazapine. <i>BMJ Case Rep</i>. 2018;2018:bcr2018224676. doi:10.1136/bcr-2018-224676<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/30344142/pubmed" id="30344142" target="_blank">30344142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25689290">
<a name="25689290"></a>Smit M, Wennink H, Heres M, Dolman KM, Honig A. Mirtazapine in pregnancy and lactation: data from a case series. <i>Clin Psychopharmacol</i>. 2015;35(2):163-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25689290/pubmed" id="25689290" target="_blank">25689290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9671349">
<a name="9671349"></a>Soutullo CA, McElroy SL, Keck PE Jr. Hypomania associated with mirtazapine augmentation of sertraline. <i>J Clin Psychiatry</i>. 1998;59(6):320. doi:10.4088/jcp.v59n0608e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/9671349/pubmed" id="9671349" target="_blank">9671349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31824812">
<a name="31824812"></a>Spitznogle B, Gerfin F. Pruritus associated with abrupt mirtazapine discontinuation: single case report. <i>Ment Health Clin</i>. 2019;9(6):401-403. doi:10.9740/mhc.2019.11.401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/31824812/pubmed" id="31824812" target="_blank">31824812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25118079">
<a name="25118079"></a>Stuhec M, Alisky J, Malesic I. Mirtazapine associated with drug-related thrombocytopenia: a case report. <i>J Clin Psychopharmacol</i>. 2014;34(5):662-664. doi:10.1097/JCP.0000000000000201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25118079/pubmed" id="25118079" target="_blank">25118079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30511003">
<a name="30511003"></a>Sukhdeo K, Yoon GH, Rothman L, Meehan SA, Levin MK, Kim RH. Mirtazapine-induced hyperpigmentation with type II histopathologic findings. <i>JAAD Case Rep</i>. 2018;4(10):1077-1079. doi:10.1016/j.jdcr.2018.09.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/30511003/pubmed" id="30511003" target="_blank">30511003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23217660">
<a name="23217660"></a>Terevnikov V, Stenberg JH, Tiihonen J, et al. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial. <i>Int J Neuropsychopharmacol</i>. 2013;16(7):1661-1666. doi:10.1017/S146114571200137X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/23217660/pubmed" id="23217660" target="_blank">23217660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28427497">
<a name="28427497"></a>Thomas E, Haboubi H, Williams N, Lloyd A, Ch'ng CL. Mirtazapine-induced steatosis. <i>Int J Clin Pharmacol Ther</i>. 2017;55(7):630-632. doi:10.5414/CP202983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/28427497/pubmed" id="28427497" target="_blank">28427497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19512989">
<a name="19512989"></a>Tonn P, Reuter SC, Hiemke C, et al, "High Mirtazapine Plasma Levels in Infant After Breast Feeding: Case Report and Review of the Literature," <i>J Clin Psychopharmacol</i>, 2009, 29(2):191-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19512989/pubmed" id="19512989" target="_blank">19512989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11351116">
<a name="11351116"></a>Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. <i>Psychosomatics</i>. 2001;42(3):258-260. doi:10.1176/appi.psy.42.3.258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/11351116/pubmed" id="11351116" target="_blank">11351116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12671522">
<a name="12671522"></a>Ubogu EE, Katirji B. Mirtazapine-induced serotonin syndrome. <i>Clin Neuropharmacol</i>. 2003;26(2):54-57. doi:10.1097/00002826-200303000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/12671522/pubmed" id="12671522" target="_blank">12671522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25467076">
<a name="25467076"></a>Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. <i>Gen Hosp Psychiatry</i>. 2015;37(1):46-48. doi:10.1016/j.genhosppsych.2014.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25467076/pubmed" id="25467076" target="_blank">25467076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.1">
<a name="VADoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf</a>. Updated February 2022. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32668640">
<a name="32668640"></a>Vayne C, Guéry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. <i>J Clin Med</i>. 2020;9(7):2212. doi:10.3390/jcm9072212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/32668640/pubmed" id="32668640" target="_blank">32668640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26816474">
<a name="26816474"></a>Verma JK, Mohapatra S. Mirtazapine withdrawal-induced mania. <i>J Pharmacol Pharmacother</i>. 2015;6(4):214-215. doi:10.4103/0976-500X.171878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26816474/pubmed" id="26816474" target="_blank">26816474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26003261">
<a name="26003261"></a>Waldinger MD. Psychiatric disorders and sexual dysfunction. <i>Handb Clin Neurol</i>. 2015;130:469-489. doi:10.1016/B978-0-444-63247-0.00027-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/26003261/pubmed" id="26003261" target="_blank">26003261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22161405">
<a name="22161405"></a>Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressive agents for depression. <i>Cochrane Database Syst Rev.</i> 2011;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/22161405/pubmed" id="22161405" target="_blank">22161405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25599460">
<a name="25599460"></a>Wichniak A, Jarkiewicz M, Okruszek Ł, Wierzbicka A, Holka-Pokorska J, Rybakowski JK. Low risk for switch to mania during treatment with sleep promoting antidepressants. <i>Pharmacopsychiatry</i>. 2015;48(3):83-88. doi:10.1055/s-0034-1396802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/25599460/pubmed" id="25599460" target="_blank">25599460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27333965">
<a name="27333965"></a>Wu CS, Tong SH, Ong CT, Sung SF. Serotonin syndrome induced by combined use of mirtazapine and olanzapine complicated with rhabdomyolysis, acute renal failure, and acute pulmonary edema-a case report. <i>Acta Neurol Taiwan</i>. 2015;24(4):117-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/27333965/pubmed" id="27333965" target="_blank">27333965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522528">
<a name="30522528"></a>Yamada Y, Takano H, Yamada M, et al. Pisa syndrome associated with mirtazapine: a case report. <i>BMC Pharmacol Toxicol</i>. 2018;19(1):82. doi:10.1186/s40360-018-0272-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/30522528/pubmed" id="30522528" target="_blank">30522528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi:10.1111/bdi.12609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19644232">
<a name="19644232"></a>Yeh YW, Chen CH, Feng HM, Wang SC, Kuo SC, Chen CK. New onset somnambulism associated with different dosage of mirtazapine: a case report. <i>Clin Neuropharmacol</i>. 2009;32(4):232-233. doi:10.1097/WNF.0b013e318187bafc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19644232/pubmed" id="19644232" target="_blank">19644232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al, “The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,” <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirtazapine-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yoon.2018">
<a name="Yoon.2018"></a>Yoon WT. Hyperkinetic movement disorders induced by mirtazapine: unusual care report and clinical analysis of reported cases. <i>J Psychiatry</i>. 2018;21(2):437. doi:10.4172/2378-5756.1000437</div>
</li></ol></div><div id="topicVersionRevision">Topic 9656 Version 563.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
